Loading patent…
AssigneeAerovance, Inc.
InventorsClark Pan, Steve Roczniak, Jeffrey Michael Greve, Stephanie L. Yung, Malinda Longphre, Teresa Mo-fun Wong, Adrian Tomkinson
Estimating the term…
This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These modified IL-4 mutein receptor antagonists, compositions and methods provide a treatment option for those individuals afflicted with a respiratory disorder such as asthma by inhibiting IL-4 and IL-13-mediated airway hyperresponsiveness and eosinophilia. More particularly, these antagonists have an increased duration of effect versus unmodified IL-4RA by virtue of a greater plasma half-life.
A modified IL-4 mutein receptor antagonist wherein the amino acid residue at position 37, 38, or 104 is cysteine and produced by
A modified IL-4 mutein receptor antagonist coupled to a non-protein polymer at an amino acid residue at position 37, 38, or 104 of IL-4, wherein the amino acid at 37, 38 or 104 is cysteine, and wherein the non-protein polymer is polyethylene glycol, polypropylene glycol or a polyoxyalkylene.
A modified IL-4 mutein receptor antagonist wherein the amino acid at 37, 38 and 104 is cysteine, and produced by
Dependencies are inferred from the claim text.